Diana Duro

List of Publications by Year
in descending order

36 papers	947 citations	471477 17 h-index	454934 30 g-index
39 all docs	39 docs citations	39 times ranked	1750 citing authors

#	Article	IF	Citations
1	Toulouse-PiÃ©ron Cancellation Test: Normative scores for the portuguese population. Applied Neuropsychology Adult, 2023, 30, 169-175.	1.2	8
2	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	3.1	1
3	Lewy body dementia is associated with an increased risk of atrial fibrillation: A case-control study. Journal of Clinical Neuroscience, 2022, 99, 62-65.	1.5	2
4	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.8	36
5	Neuropsychological features of progranulin-associated frontotemporal dementia: a nested case-control study. Neural Regeneration Research, 2021, 16, 910.	3.0	3
6	DEPDC5 variant in focal cortical dysplasia: a case report and review of the literature. Oxford Medical Case Reports, 2021, 2021, omab027.	0.4	1
7	APOE É›4-TOMM40L Haplotype Increases the Risk of Mild Cognitive Impairment Conversion to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 78, 587-601.	2.6	0
8	Patients with progranulin mutations overlap with the progressive dysexecutive syndrome: towards the definition of a frontoparietal dementia phenotype. Brain Communications, 2020, 2, fcaa126.	3.3	3
9	Face-Specific Perceptual Distortions Reveal A View- and Orientation-Independent Face Template. Current Biology, 2020, 30, 4071-4077.e4.	3.9	15
10	C-reactive protein as a predictor of mild cognitive impairment conversion into Alzheimer's disease dementia. Experimental Gerontology, 2020, 138, 111004.	2.8	18
11	Increased CSF tau is associated with a higher risk of seizures in patients with Alzheimer's disease. Epilepsy and Behavior, 2019, 98, 207-209.	1.7	22
12	Lower CSF Amyloid-Beta1â€“42 Predicts a Higher Mortality Rate in Frontotemporal Dementia. Diagnostics, 2019, 9, 162.	2.6	3
13	Association between Adipokines and Biomarkers of Alzheimerâ€™s Disease: A Cross-Sectional Study. Journal of Alzheimer's Disease, 2019, 67, 725-735.	2.6	18
14	Discriminative capacity and construct validity of the Clock Drawing Test in Mild Cognitive Impairment and Alzheimerâ€™s disease. Clinical Neuropsychologist, 2019, 33, 1159-1174.	2.3	5
15	Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 2.	6.2	19
16	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	3.1	47
17	Clock drawing test in mild cognitive impairment: Correlation with cerebral perfusion in single-photon emission computed tomography.. Neuropsychology, 2019, 33, 617-632.	1.3	10
18	Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration. Journal of Alzheimer's Disease, 2018, 64, S647-S657.	2.6	10

#	Article	IF	Citations
19	Validation study of the Alzheimerâ€™s disease assessment scaleâ€“cognitive subscale (ADAS-Cog) for the Portuguese patients with mild cognitive impairment and Alzheimerâ€™s disease. Clinical Neuropsychologist, 2018, 32, 46-59.	2.3	24
20	Escala de AvaliaÃ§Ã£o da DoenÃ§a de Alzheimer - Subescala Cognitiva (ADAS-Cog): Dados Normativos para a PopulaÃ§Ã£o Portuguesa. Acta Medica Portuguesa, 2018, 31, 94.	0.4	8
21	Addition of the AÎ²42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimerâ€™s disease dementia in mild cognitive impairment. Alzheimer's Research and Therapy, 2018, 10, 33.	6.2	63
22	Validity and Clinical Utility of Different Clock Drawing Test Scoring Systems in Multiple Forms of Dementia. Journal of Geriatric Psychiatry and Neurology, 2018, 31, 114-122.	2.3	12
23	The Head Turning Sign in Dementia and Mild Cognitive Impairment: Its Relationship to Cognition, Behavior, and Cerebrospinal Fluid Biomarkers. Dementia and Geriatric Cognitive Disorders, 2018, 46, 42-49.	1.5	6
24	Prognosis of Early-Onset vs. Late-Onset Mild Cognitive Impairment: Comparison of Conversion Rates and Its Predictors. Geriatrics (Switzerland), 2016, 1, 11.	1.7	38
25	MicroRNA deregulation and chemotaxis and phagocytosis impairment inÂAlzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 7-17.	2.4	51
26	Genetic Variation of <i>MT-ND</i> Genes in Frontotemporal Lobar Degeneration: Biochemical Phenotype-Genotype Correlation. Neurodegenerative Diseases, 2015, 15, 70-80.	1.4	1
27	Cerebrospinal fluid AÎ²40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease. Journal of the Neurological Sciences, 2015, 358, 308-316.	0.6	25
28	Frontotemporal dementia: neuroanatomical correlates of an atypical presentation. BMJ Case Reports, 2014, 2014, bcr2014205089-bcr2014205089.	0.5	3
29	The Free and Cued Selective Reminding Test Distinguishes Frontotemporal Dementia From Alzheimer's Disease. Archives of Clinical Neuropsychology, 2014, 29, 670-679.	0.5	50
30	The Clock Drawing Test: Portuguese Norms, by Age and Education, for Three Different Scoring Systems. Archives of Clinical Neuropsychology, 2013, 28, 375-387.	0.5	22
31	Multiple Dural Arteriovenous Fistulas Presenting as Rapidly Progressive Dementia. Neurologist, 2012, 18, 130-132.	0.7	17
32	Montreal Cognitive Assessment (MoCA): Validation study for Frontotemporal Dementia. Journal of Geriatric Psychiatry and Neurology, 2012, 25, 146-154.	2.3	66
33	Validation studies of the Portuguese experimental version of the Montreal Cognitive Assessment (MoCA): confirmatory factor analysis. Journal of Neurology, 2010, 257, 728-734.	3.6	79
34	Oxidative Damage and Progression to Alzheimer's Disease in Patients with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 21, 1165-1177.	2.6	78
35	Peripheral Oxidative Damage in Mild Cognitive Impairment and Mild Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 15, 117-128.	2.6	133
36	Elevated serum adiponectin in Alzheimer's disease as neuroprotective strategy. Endocrine Abstracts, 0, , .	0.0	0